Kelly A Cairns1,2, Joseph S Doyle3, Janine M Trevillyan3, Kylie Horne4, Rhonda L Stuart4,5, Nicole Bushett6, Michelle K Yong3, Peter G Kelley3, Michael J Dooley1,2, Allen C Cheng7,8,9. 1. Pharmacy Department, Alfred Health, 55 Commercial Rd, Prahran, VIC, Australia. 2. Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, Australia. 3. Department of Infectious Diseases, Alfred Health and Monash University, 55 Commercial Rd, Prahran, VIC, Australia. 4. Monash Infectious Diseases, Monash Health, 246 Clayton Rd, Clayton, VIC, Australia. 5. Department of Medicine, Monash University, 246 Clayton Rd, Clayton, VIC, Australia. 6. Pharmacy Department, Monash Health, 246 Clayton Rd, Clayton, VIC, Australia. 7. Department of Infectious Diseases, Alfred Health and Monash University, 55 Commercial Rd, Prahran, VIC, Australia allen.cheng@monash.edu. 8. School of Public Health and Preventive Medicine, Monash University, Alfred Centre, 99 Commercial Road, Melbourne VIC, Australia. 9. Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, 2nd floor, Burnet Centre, 85 Commercial Road, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Antimicrobial stewardship teams play an important role in assisting with the optimization of antimicrobial use in acute care settings. We aimed to determine whether a rapid review by a multidisciplinary antimicrobial stewardship team would improve the timeliness of optimal antimicrobial therapy for patients with positive blood cultures. METHODS: This prospective randomized controlled trial was undertaken in two Australian hospitals. Patients received either standard care (a clinical microbiologist, registrar or laboratory scientist communicating the positive blood culture by phone to the treating doctor) or intervention (standard care plus rapid review by a multidisciplinary antimicrobial stewardship team). Outcomes included time to appropriate and/or active antimicrobial therapy and in-hospital mortality. The trial was registered on the Australian New Zealand Clinical Trials Registry (ACTRN12614000258651). RESULTS: A total of 160 patients were enrolled in this study: 81 in the standard care arm and 79 in the intervention arm. Patients in the intervention arm were commenced earlier on active (HR 8.02, 95% CI: 2.15-29.91) and appropriate antimicrobials (HR 1.95, 95% CI: 1.13-3.38), with a higher proportion of patients allocated to the intervention arm receiving active therapy at 48 h (96% versus 82%) and appropriate therapy at 72 h (70% versus 54%). The majority of patients where the blood culture was a contaminant were not started on antimicrobial therapy, and there were no significant differences in time to cessation of antimicrobial therapy. CONCLUSIONS: Antimicrobial stewardship team review of patients with pathogenic positive blood cultures improved the time to both active and appropriate antimicrobial therapy.
RCT Entities:
BACKGROUND: Antimicrobial stewardship teams play an important role in assisting with the optimization of antimicrobial use in acute care settings. We aimed to determine whether a rapid review by a multidisciplinary antimicrobial stewardship team would improve the timeliness of optimal antimicrobial therapy for patients with positive blood cultures. METHODS: This prospective randomized controlled trial was undertaken in two Australian hospitals. Patients received either standard care (a clinical microbiologist, registrar or laboratory scientist communicating the positive blood culture by phone to the treating doctor) or intervention (standard care plus rapid review by a multidisciplinary antimicrobial stewardship team). Outcomes included time to appropriate and/or active antimicrobial therapy and in-hospital mortality. The trial was registered on the Australian New Zealand Clinical Trials Registry (ACTRN12614000258651). RESULTS: A total of 160 patients were enrolled in this study: 81 in the standard care arm and 79 in the intervention arm. Patients in the intervention arm were commenced earlier on active (HR 8.02, 95% CI: 2.15-29.91) and appropriate antimicrobials (HR 1.95, 95% CI: 1.13-3.38), with a higher proportion of patients allocated to the intervention arm receiving active therapy at 48 h (96% versus 82%) and appropriate therapy at 72 h (70% versus 54%). The majority of patients where the blood culture was a contaminant were not started on antimicrobial therapy, and there were no significant differences in time to cessation of antimicrobial therapy. CONCLUSIONS: Antimicrobial stewardship team review of patients with pathogenic positive blood cultures improved the time to both active and appropriate antimicrobial therapy.
Authors: Carina Schuster; Sebastian Sterz; Daniel Teupser; Mathias Brügel; Michael Vogeser; Michael Paal Journal: J Vis Exp Date: 2018-08-30 Impact factor: 1.355
Authors: Brandon J Tritle; Robert Watteyne; Abby Hickman; Todd J Vento; Bert K Lopansri; Dave S Collingridge; John J Veillette Journal: Hosp Pharm Date: 2021-08-08
Authors: Zohal Rashidzada; Kelly A Cairns; Trisha N Peel; Adam W Jenney; Joseph S Doyle; Michael J Dooley; Allen C Cheng Journal: JAC Antimicrob Resist Date: 2021-08-27
Authors: Anucha Apisarnthanarak; Hong Bin Kim; Luke S P Moore; Yonghong Xiao; Sanjeev Singh; Yohei Doi; Andrea Lay-Hoon Kwa; Sasheela Sri La Sri Ponnampalavanar; Qing Cao; Shin-Woo Kim; Hyukmin Lee; Pitak Santanirand Journal: Clin Infect Dis Date: 2022-06-10 Impact factor: 20.999